Acrivon Therapeutics, Inc. Share Price

Acrivon Therapeutics, Inc. Share Price

NASDAQ: ACRV | Micro Cap
$1.78
+$0.01 (0.28%) Last updated on 29 Oct, 2026 | 20:58 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Acrivon Therapeutics, Inc. Stock Performance

Open
$1.82
Prev. Close
$1.77
Circuit Range
N/A
Day Range
$1.82 - $1.82
Year Range
$1.27 - $3.54
Volume
478
Average Traded
$1.82

Acrivon Therapeutics, Inc. Share Price Today

As of 29 October 2026, Acrivon Therapeutics, Inc.'s share price is $1.78. The stock opened at $1.82, compared to its previous close of $1.77. During today's trading session, Acrivon Therapeutics, Inc.'s share price traded between $1.82 and $1.82, with an average price of $1.82. Over the past 52 weeks, the stock has recorded a high of $3.54 and a low of $1.27. In terms of performance, Acrivon Therapeutics, Inc.'s share price has declined by 3.78% over the last six months and is down 10.10% on a year-on-year basis.

Acrivon Therapeutics, Inc. Share Price Chart

Line chart of the Acrivon Therapeutics, Inc. price trend over the selected period. The price rose overall, ranging from 1.77 to 1.83, ending at 1.78.
$1.82$1.82
L
Show Current Price
H

Acrivon Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$68.55M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.73
Revenue (TTM)
$0.00
Return On Equity (TTM)
-85.65%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
1.48%

Acrivon Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$18.23-$18.99-$19.04-$17.96
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-4.17%-0.26%5.67%

Acrivon Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$31.17-$60.39-$80.56-$77.91
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-93.74%-33.40%3.29%

About Acrivon Therapeutics, Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Acrivon Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$2.06
$1.82
-11.22%
Sep 2026
$2.04
$2.05
-5.09%
Aug 2026
$1.49
$2.16
+43.05%
Jul 2026
$1.77
$1.51
-15.17%
Jun 2026
$1.58
$1.78
+10.22%
May 2026
$1.88
$1.61
-12.70%
Apr 2026
$1.46
$1.85
+32.14%
Mar 2026
$1.48
$1.40
-7.59%
Feb 2026
$1.75
$1.51
-15.13%
Jan 2026
$2.39
$1.78
-26.09%
Dec 2025
$2.37
$2.42
+1.90%
Nov 2025
$2.26
$2.37
+19.70%

ACRV Share Price FAQs